Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 13/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4264000 | 0.99 | MCHR1 (0.61) | MCHR1ADRA2ANPY5REPHX2MALT1 | |
| SCHEMBL6462492 | 0.85 | MCHR1 (0.66) | MCHR1ADRA2ANPY5REPHX2HRH4 | |
| Hydrochloric Acid SCHEMBL6455453 | 0.84 | MCHR1 (0.65) | MCHR1ADRA2ANPY5REPHX2HRH4 | |
| SCHEMBL4266637 | 0.84 | MCHR1 (0.60) | MCHR1ADRA2ANPY5REPHX2CYP1A2 | |
| SCHEMBL4266633 | 0.84 | MCHR1 (0.60) | MCHR1ADRA2ANPY5REPHX2CYP1A2 | |
| Hydrochloric Acid SCHEMBL4266674 | 0.83 | MCHR1 (0.59) | MCHR1ADRA2ANPY5REPHX2CYP1A2 | |
| Hydrochloric Acid SCHEMBL4266669 | 0.83 | MCHR1 (0.59) | MCHR1ADRA2ANPY5REPHX2CYP1A2 | |
| SCHEMBL5669859 | 0.82 | MCHR1 (0.56) | MCHR1ADRA2ANPY5REPHX2HRH4 | |
| SCHEMBL23124560 | 0.81 | MCHR1 (0.59) | MCHR1ADRA2ANPY5REPHX2CYP1A2 | |
| SCHEMBL6457443 | 0.80 | MCHR1 (0.73) | MCHR1ADRA2ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | MCHR1 3/4885ADRA2A 178/4885NPY5R 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.